Lupin’s U.S. Arm Settles Humana Antitrust Claim for $30 Million

The latest announcement is out from Lupin Limited ( (IN:LUPIN) ).

Lupin’s U.S. subsidiary, Lupin Pharmaceuticals, Inc., has been a defendant in consolidated civil antitrust litigation in Philadelphia over alleged anticompetitive conduct involving certain generic drug products. While the company maintains that the allegations are unfounded, it has opted to resolve one strand of the dispute with plaintiff Humana Inc. through a negotiated settlement.

Under the settlement, Lupin Pharmaceuticals will pay USD 30 million to Humana in exchange for a full and final release of all claims against the company and its affiliated entities, with the payment already provisioned in Lupin’s consolidated financial results. The agreement, which follows similar settlements by other defendants, allows Lupin to avoid further legal costs and uncertainty without admitting liability, limiting financial surprise for investors and providing greater clarity around one aspect of its U.S. legal exposures.

More about Lupin Limited

Lupin Limited is an India-headquartered global pharmaceutical company operating through subsidiaries such as Lupin Pharmaceuticals, Inc. in the U.S. It focuses on generic and specialty medicines, serving regulated markets including the United States, and is listed on both the National Stock Exchange of India and BSE Limited.

Average Trading Volume: 30,261

Technical Sentiment Signal: Buy

Current Market Cap: 1069.4B INR

See more data about LUPIN stock on TipRanks’ Stock Analysis page.